Acute myocardial infarction in a patient with von Willebrand disease: Pathogenetic dilemmas and therapeutic challenges

Journal of Invasive Cardiology

Volumn 14, Issue 10, 2002, Pages 615-618

  Arjomand, Heidar ^a   Aquilina, Patrick ^a   McCormick, Daniel ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

Author keywords

Antiplatelet therapy; Myocardial infarction; Von Willebrand disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CAPTOPRIL; CLOPIDOGREL; HEPARIN; METOPROLOL; PRAVASTATIN; TIROFIBAN;

ACUTE HEART INFARCTION; ADULT; ANTICOAGULATION; ARTICLE; CASE REPORT; CORONARY ARTERY DILATATION; ECHOCARDIOGRAPHY; FEMALE; GENETIC DISORDER; HEART CATHETERIZATION; HUMAN; INTERVENTIONAL RADIOLOGY; PATHOGENESIS; VON WILLEBRAND DISEASE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; STENTS; TREATMENT OUTCOME; VON WILLEBRAND DISEASE;

EID: 0036793546     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Coller BS. Inherited disorders of platelet function. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EDG (eds). Hemostasis and Thrombosis, 2nd Edition. New York, Churchill Livingstone, 1994: pp. 721-766.
2. Federici AB, Mannucci PM, Fogato E, et al. Autopsy findings in three patients with von Willebrand disease type IIb and type III: Presence of atherosclerotic lesions without occlusive arterial thrombi. Thromb Haemost 1993;70:758-761.
3. Griggs TR, Reddick RL, Sultzer D, Brinkhous KM. Susceptibility to atherosclerosis in aortas and coronary arteries of swine with von Willebrand's disease. Am J Pathol 1981;102:137-145.
4. Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: A report of 21 patients and review of 50 previously reported cases. Medicine (Baltimore) 1983;62:248-255.
5. Wong CB, Schreiber TL. Acute myocardial infarction in a patient with von Willebrand disease. Cathet Cardiovasc Diagn 1996;38:287-288.
6. Fragasso G, Camba L, Pizzetti G, et al. Successful thrombolysis for acute myocardial infarction in type I von Willebrand disease (vWD). Am J Hematol 1998;57:180.
7. Fuster V, Bowie EJW, Lewis JC, et al. Resistance to arteriosclerosis in pigs with von Willebrand's disease. J Clin Invest 1978;61:722-730.
8. Fuster V, Lie JT, Badimon L, et al. Spontaneous and diet-induced coronary atherosclerosis in normal swine and swine with von Willebrand disease. Arteriosclerosis 1985;5:67-73.
9. Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-641.
10. Montalescot G, Collet JP, Lison L, et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. JAm Coll Cardiol 2000;36:110-114.
11. Jansson JH, Nilsson TK, Johnson O. Von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10-year follow-up of survivors of acute myocardial infarction. Heart 1998;80:334-337.
12. Montalescot G, Barragan P, Wittenberg O, et al., for the ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
13. Arjomand H, Mascarenhas D. Combination of abciximab with primary stenting in patients with acute myocardial infarction: A community hospital experience. J Invas Cardiol 2000;12:125-129.
14. TARGET 6-month results: Tirofiban catching up. www.theheart.org (accessed 8/7/2001).
15. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 2000;35:1103-1115.